CYMABAY THERAPEUTICS, INC. Inactive Instrument
CymaBay Therapeutics, Inc.
Equities
CBAY
US23257D1037
Biotechnology & Medical Research
Presenter SpeechRaji Gunasekera (Analysts)Hi. Good afternoon. Welcome to the JPMorgan Healthca...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with liver and other chronic diseases. The Company's lead product candidate, seladelpar (MBX-8025), is a potent and selective agonist of peroxisome proliferator-activated receptor delta (PPARd), a nuclear receptor that regulates genes directly or indirectly involved in the synthesis of bile acids/sterols, metabolism of lipids and glucose, inflammation and fibrosis. The Company is focused on developing seladelpar for the treatment of primary biliary cholangitis (PBC), an autoimmune disease that causes progressive destruction of the bile ducts in the liver resulting in impaired bile flow (cholestasis) and inflammation.
Related indices
| 1st Jan change | Capi. | |
|---|---|---|
| -2.19% | 103B | |
| +1.76% | 95.28B | |
| +1.46% | 22.15B | |
| -15.72% | 21.02B | |
| -8.58% | 18.15B | |
| -38.74% | 16.73B | |
| -13.17% | 16.05B | |
| +4.74% | 13.68B | |
| +36.41% | 12.17B |
